| 1 |
Ferlay J,Soerjomataram I,Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 [J]. Int J Cancer, 2015, 136(5): E359-386.
|
| 2 |
Chen W,Zheng R,Baade PD, et al. Cancer statistics in China, 2015 [J]. CA Cancer J Clin, 2016, 66(2): 115-132.
|
| 3 |
Siegel RL,Miller KD,Jemal A. Cancer Statistics, 2017 [J]. CA Cancer J Clin, 2017, 67(1): 7-30.
|
| 4 |
Siegel RL,Miller KD,Fedewa SA, et al. Colorectal cancer statistics, 2017 [J]. CA Cancer J Clin, 2017, 67(3): 177-193.
|
| 5 |
Murphy CC,Harlan LC,Lund JL, et al. Patterns of Colorectal Cancer Care in the United States: 1990-2010 [J]. J Natl Cancer Inst, 2015, 107(10): pii: djv198.
|
| 6 |
National Center for Health Statistics(US).Health, United States, 2015: With Special Feature on Racial and Ethnic Health Disparities. Hyattsville (MD) 2016[R].2016 May, Report No.: 2016-1232.
|
| 7 |
Smith RA,Andrews KS,Brooks D, et al. Cancer screening in the United States, 2017: A review of current American Cancer Society guidelines and current issues in cancer screening [J]. CA Cancer J Clin, 2017, 67(2): 100-121.
|
| 8 |
Andre T,Boni C,Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer [J]. N Engl J Med, 2004, 350(23): 2343-2351.
|
| 9 |
Wong RK,Tandan V,De Silva S, et al. Pre-operative radiotherapy and curative surgery for the management of localized rectal carcinoma [J]. Cochrane Database Syst Rev, 2007(2): CD002102.
|
| 10 |
Sauer R,Becker H,Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer [J]. N Engl J Med, 2004, 351(17): 1731-1740.
|
| 11 |
Wancata LM,Banerjee M,Muenz DG, et al. Conditional survival in advanced colorectal cancer and surgery [J]. J Surg Res, 2016, 201(1): 196-201.
|
| 12 |
Chua TC,Saxena A,Chu F, et al. Predictors of cure after hepatic resection of colorectal liver metastases: an analysis of actual 5- and 10-year survivors [J]. J Surg Oncol, 2011, 103(8): 796-800.
|
| 13 |
Saltz LB,Clarke S,Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study [J]. J Clin Oncol, 2008, 26(12): 2013-2019.
|
| 14 |
Duggan MA,Anderson WF,Altekruse S, et al. The Surveillance, Epidemiology, and End Results (SEER) Program and Pathology: Toward Strengthening the Critical Relationship [J]. Am J Surg Pathol, 2016, 40(12): e94-e102.
|
| 15 |
Edwards BK,Ward E,Kohler BA, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates [J]. Cancer, 2010, 116(3): 544-573.
|
| 16 |
Aleksandrova K,Pischon T,Jenab M, et al. Combined impact of healthy lifestyle factors on colorectal cancer: a large European cohort study [J]. BMC Med, 2014, 12: 168.
|
| 17 |
Kabat GC,Matthews CE,Kamensky V, et al. Adherence to cancer prevention guidelines and cancer incidence, cancer mortality, and total mortality: a prospective cohort study [J]. Am J Clin Nutr, 2015, 101(3): 558-569.
|
| 18 |
Song M,Giovannucci E. Preventable Incidence and Mortality of Carcinoma Associated With Lifestyle Factors Among White Adults in the United States [J]. JAMA Oncol, 2016, 2(9): 1154-1161.
|
| 19 |
Vogelaar I,van Ballegooijen M,Schrag D, et al. How much can current interventions reduce colorectal cancer mortality in the U.S.? Mortality projections for scenarios of risk-factor modification, screening, and treatment [J]. Cancer, 2006, 107(7): 1624-1633.
|
| 20 |
王锡山. 结直肠肿瘤治疗的微创和功能外科理念在实践与探索中前行 [J]. 中华结直肠疾病电子杂志, 2013, 2(3): 106-108.
|